2023
An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis
LaMarche N, Hegde S, Park M, Maier B, Troncoso L, Le Berichel J, Hamon P, Belabed M, Mattiuz R, Hennequin C, Chin T, Reid A, Reyes-Torres I, Nemeth E, Zhang R, Olson O, Doroshow D, Rohs N, Gomez J, Veluswamy R, Hall N, Venturini N, Ginhoux F, Liu Z, Buckup M, Figueiredo I, Roudko V, Miyake K, Karasuyama H, Gonzalez-Kozlova E, Gnjatic S, Passegué E, Kim-Schulze S, Brown B, Hirsch F, Kim B, Marron T, Merad M. An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis. Nature 2023, 625: 166-174. PMID: 38057662, PMCID: PMC11189607, DOI: 10.1038/s41586-023-06797-9.Peer-Reviewed Original ResearchConceptsInterleukin-4IL-4RαMyeloid cellsCheckpoint blockadeTumor burdenPD-1/PD-L1 checkpoint blockadePD-1/PD-L1 blockadeBone marrowTumor-infiltrating CD8 T cellsType 2 cytokines interleukin-4PD-L1 checkpoint blockadeCell lung cancer lesionsNon-small cell lung cancer lesionsDepletion of basophilsPD-L1 blockadePrimary disease siteCD8 T cellsImmune checkpoint blockadeLung cancer lesionsNovel combination therapiesCytokine interleukin-4Bone marrow basophilsConditional knockout miceRefractory NSCLCEarly myeloid progenitorsEnfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV-103 cohort K.
O'Donnell P, Rosenberg J, Hoimes C, Petrylak D, Milowsky M, McKay R, Srinivas S, Friedlander T, Ramamurthy C, Bilen M, Burgess E, Mar N, Moon H, Geynisman D, George S, Carret A, Yu Y, Guseva M, Moreno B, Flaig T. Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV-103 cohort K. Journal Of Clinical Oncology 2023, 41: 499-499. DOI: 10.1200/jco.2023.41.6_suppl.499.Peer-Reviewed Original ResearchLiver metastasesDay 1Disease sitesPD-L1 expression statusBlinded independent central reviewAppropriate dose modificationCisplatin-ineligible patientsManageable safety profileMetastatic urothelial cancerObjective response rateECOG PS scorePhase 3 trialPre-specified subgroupsPrimary disease siteDuration of responseIndependent central reviewMetastatic disease sitesHigh unmet needECOG PSMedian DORRECIST v1.1Untreated LAOverall cohortPrimary endpointSecondary endpoints
2020
Neuroendocrine and carcinoid tumors of the gastrointestinal tract: Epidemiology and outcomes from the National Cancer Database.
Uhlig J, Nie J, Stein S, Cecchini M, Lacy J, Kim H. Neuroendocrine and carcinoid tumors of the gastrointestinal tract: Epidemiology and outcomes from the National Cancer Database. Journal Of Clinical Oncology 2020, 38: 609-609. DOI: 10.1200/jco.2020.38.4_suppl.609.Peer-Reviewed Original ResearchNational Cancer DatabaseNeuroendocrine tumorsOverall survivalSmall intestineSurgical resectionYounger patientsCancer DatabaseGastrointestinal tractImproved overall survivalPrimary disease siteLonger overall survivalPrimary cancer siteProportional hazards modelAfrican AmericansLower stageConcurrent chemotherapyMultivariable adjustmentAdult patientsMost metastasesPatient agePatient demographicsIndependent prognosticatorCarcinoid tumorsHepatic metastasesTumor size
2019
Emergency Department Visits for Opioid Overdoses Among Patients With Cancer
Jairam V, Yang DX, Yu JB, Park HS. Emergency Department Visits for Opioid Overdoses Among Patients With Cancer. Journal Of The National Cancer Institute 2019, 112: 938-943. PMID: 31845985, PMCID: PMC7492769, DOI: 10.1093/jnci/djz233.Peer-Reviewed Original ResearchConceptsOpioid-related ED visitsED visitsEmergency departmentOpioid overdoseComorbid diagnosesUtilization Project Nationwide Emergency Department SampleMultivariable logistic regression analysisNationwide Emergency Department SampleHigh opioid useOpioid-related visitsPrimary disease siteEmergency department visitsEmergency Department SampleLogistic regression analysisSubstance use disordersOpioid useDepartment visitsChronic painMultiple myelomaNeck cancerPrimary diagnosisRisk factorsPatient visitsBaseline differencesOpioid overdosesTrends and Disparities of Proton Therapy Use among Patients with Head and Neck Cancer: Analysis from the National Cancer Database (2005-14)
Lee A, Kang J, Yu Y, McBride S, Riaz N, Cohen M, Sherman E, Michel L, Lee N, Tsai CJ. Trends and Disparities of Proton Therapy Use among Patients with Head and Neck Cancer: Analysis from the National Cancer Database (2005-14). International Journal Of Particle Therapy 2019, 5: 1-10. PMID: 31773036, PMCID: PMC6871620, DOI: 10.14338/ijpt-19-00051.1.Peer-Reviewed Original ResearchNational Cancer DatabasePrimary disease siteMultivariable logistic regressionTherapy useNeck cancerRadiation therapyCancer DatabasePrimary siteDisease sitesNasal cavity/nasopharynxLogistic regressionInitial treatment courseNeck primary malignancyProton therapyCommon primary siteDistribution of patientsHousehold income quartileT4 diseaseMost patientsPrimary malignancyClinical factorsNonmetastatic headTreatment coursePrimary headOral cavity
2015
National treatment patterns in patients presenting with Stage IVC head and neck cancer: analysis of the National Cancer Database
Schwam ZG, Burtness B, Yarbrough WG, Mehra S, Husain Z, Judson BL. National treatment patterns in patients presenting with Stage IVC head and neck cancer: analysis of the National Cancer Database. Cancer Medicine 2015, 4: 1828-1835. PMID: 26471244, PMCID: PMC5123708, DOI: 10.1002/cam4.546.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overCombined Modality TherapyComorbidityDatabases, FactualFemaleHead and Neck NeoplasmsHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPopulation SurveillanceRetrospective StudiesRisk FactorsTreatment OutcomeUnited StatesYoung AdultConceptsNational Cancer DatabaseSystemic therapyPalliative therapyTreatment patternsNeck cancerCancer DatabaseClinical trialsMedicaid/uninsured statusCox proportional hazards analysisCommon treatment regimenNational treatment patternsCharlson comorbidity scorePrimary disease siteRetrospective cohort analysisProportional hazards analysisRisk of deathNeck cancer patientsMedicare/Comorbidity scoreMetastatic headOverall survivalSystemic treatmentTreatment regimenDistant metastasisKaplan-Meier
2013
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial
Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler J, Limaye S, Riley S, Posner M. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. The Lancet Oncology 2013, 14: 257-264. PMID: 23414589, DOI: 10.1016/s1470-2045(13)70011-1.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyCisplatinCombined Modality TherapyDisease-Free SurvivalFemaleFluorouracilFollow-Up StudiesHead and Neck NeoplasmsHumansInduction ChemotherapyKaplan-Meier EstimateMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingTaxoidsConceptsHead and neck cancerChemoradiotherapy alone groupConcurrent chemoradiotherapyInduction chemotherapyChemoradiotherapy groupNeck cancerAlone groupOverall survivalLocally advanced head and neck cancerPatients treated with induction chemotherapyOpen-label phase 3 studyInduction chemotherapy to chemoradiotherapyCisplatin-based concurrent chemoradiotherapyRandomised phase 3 trialDiagnosed head and neck cancerCycles of TPFLocally advanced headMedian Follow-UpPrimary disease siteWHO performance statusPhase 3 studyAdvanced tumor stagePhase 3 trialBolus cisplatinSequential chemoradiotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply